María E.R. García-Rendueles

Madrid Institute for Advanced Studies — Spain

Medicine · Health Sciences

15h-index1.1kcitations38works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Thyroid Cancer Diagnosis and Treatment(13), Cancer-related Molecular Pathways(8), Hippo pathway signaling and YAP/TAZ(7), Cell death mechanisms and regulation(3), Regulation of Appetite and Obesity(3)

Publications38 total

Ghrelin
Trends in Endocrinology and Metabolism·2024· 3 cited
Supplementary Figures S1 - S10, Tables S1 - S3 from <i>NF2</i> Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition
2023Open Access
Data from <i>NF2</i> Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition
2023Open Access
Data from <i>NF2</i> Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition
2023Open Access
Supplementary Figures S1 - S10, Tables S1 - S3 from <i>NF2</i> Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition
2023Open Access
Supplementary Data from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies
2023Open Access
Supplementary Tables S1-S12 from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies
2023Open Access
Supplementary Figures S1-S10 from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies
2023Open Access
Supplementary Tables S1-S12 from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies
2023Open Access
Supplementary Figures S1-S10 from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies
2023Open Access
Data from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies
2023Open Access
Supplementary Data from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies
2023Open Access
Data from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies
2023Open Access
Una proteína condenada a “trabajos forzados”, causa de resistencia del cáncer a los fármacos
2023
Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors
Molecular Cancer·2022· 28 citedOpen Access
NUCLEAR YAP INDUCES AGGRESSIVE THYROID TUMORS AND CONFERS PRIMARY RESISTANCE TO VEMURAFENIB
Journal of the ASEAN Federation of Endocrine Societies·2022Open Access
‘Vigilar y esperar’, una nueva estrategia para tratar el cáncer de tiroides
2022
Oncogenic Pathways in Neurodegenerative Diseases
International Journal of Molecular Sciences·2022· 26 citedOpen Access
Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies
Clinical Cancer Research·2019· 182 citedOpen Access
Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers
Cancer Research·2018· 77 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

James A. Fagin(19), Jeffrey A. Knauf(18), Iñigo Landa(14), Susana B. Bravo(14), Clara V. Álvarez(11), Nikita Pozdeyev(9), Christopher Korch(9), Laura A. Marlow(9), Robert C. Smallridge(9), John A. Copland(9), Ying C. Henderson(9), Stephen Y. Lai(9), Gary L. Clayman(9), Naoyoshi Onoda(9), Aik Choon Tan(9), Bryan R. Haugen(9), Rebecca E. Schweppe(9), José Cameselle‐Teijeiro(9), Ronald Ghossein(8), Joana S. Rodrigues(8)